Abstract: Background: Primary anaplastic-lymphoma-kinase (ALK)-positive large-cell lymphoma of the central nervous system (PCNS ALK-positive ALCL) is a rare entity, with a limited consensus reached regarding its management. While this pathology often presents as solitary lesions, the occurrence of multiple tumors within the brain is not uncommon. The lack of distinctive radiological features poses a diagnostic challenge, leading to delays in initiating targeted therapy. Methods: We conducted a comprehensive literature search, identifying seventeen publications for qualitative analysis. Results: The management options and reported patient outcomes in the literature varied significantly, emphasizing the need for a patient-specific approach. The emergence of ALK-specific inhibitors represents a new frontier in this field, demonstrating promising results. Conclusion: PCNS ALK-positive ALCL necessitates a comprehensive understanding and optimized management strategies. A tailored therapeutic approach, integrating surgical intervention with radiotherapy and chemotherapy, appears pivotal in addressing this pathology. The implementation of a therapeutic protocol is anticipated for further advancement in this field.
Primary anaplastic-lymphoma-kinase-positive large-cell lymphoma of the central nervous system: comprehensive review of the literature / Colamaria, Antonio; Leone, Augusto; Carbone, Francesco; Dallos Laguado, Yasser Andres; Fochi, Nicola Pio; Sacco, Matteo; Fesce, Cinzia; Sanguedolce, Francesca; Giordano, Guido; Iaconetta, Giorgio; Spetzger, Uwe; Coppola, Luigi; De Santis, Elena; Coppola, Giulia; De Notaris, Matteo. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 12:24(2023), pp. 1-12. [10.3390/jcm12247516]
Primary anaplastic-lymphoma-kinase-positive large-cell lymphoma of the central nervous system: comprehensive review of the literature
De Santis, ElenaWriting – Review & Editing
;
2023
Abstract
Abstract: Background: Primary anaplastic-lymphoma-kinase (ALK)-positive large-cell lymphoma of the central nervous system (PCNS ALK-positive ALCL) is a rare entity, with a limited consensus reached regarding its management. While this pathology often presents as solitary lesions, the occurrence of multiple tumors within the brain is not uncommon. The lack of distinctive radiological features poses a diagnostic challenge, leading to delays in initiating targeted therapy. Methods: We conducted a comprehensive literature search, identifying seventeen publications for qualitative analysis. Results: The management options and reported patient outcomes in the literature varied significantly, emphasizing the need for a patient-specific approach. The emergence of ALK-specific inhibitors represents a new frontier in this field, demonstrating promising results. Conclusion: PCNS ALK-positive ALCL necessitates a comprehensive understanding and optimized management strategies. A tailored therapeutic approach, integrating surgical intervention with radiotherapy and chemotherapy, appears pivotal in addressing this pathology. The implementation of a therapeutic protocol is anticipated for further advancement in this field.File | Dimensione | Formato | |
---|---|---|---|
Colamaria_Primary_2023.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
470.02 kB
Formato
Adobe PDF
|
470.02 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.